CONTACT US
Home > Membrane Transporter/Ion Channel>Potassium Channel> > Glimepiride
93479-97-1-Glimepiride Glimepiride

Glimepiride

For research use only. Not for therapeutic Use.

  • CAT Number: I005553
  • CAS Number: 93479-97-1
  • Molecular Formula: C24H34N4O5S
  • Molecular Weight: 490.619
  • Purity: ≥95%
Inquiry Now
Related products: Quinidine hydrochloride monohydrate     2,2,2-Trichloroethanol     Tolbutamide    
Research Areas: Diabetes and Metabolic Syndrome    

Glimepiride (CAT: I005553) is an oral medication belonging to the class of sulfonylurea drugs used for the management of type 2 diabetes mellitus. It works by stimulating the release of insulin from pancreatic beta cells and improving insulin sensitivity in peripheral tissues, thereby helping to lower blood glucose levels. Glimepiride is typically prescribed along with diet and exercise to control blood sugar levels in individuals with diabetes. It is important to follow the prescribed dosage and instructions provided by a healthcare professional when using glimepiride.


Catalog Number I005553
CAS Number 93479-97-1
Synonyms

4-ethyl-3-methyl-N-[2-[4-[(4-methylcyclohexyl)carbamoylsulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide

Molecular Formula C24H34N4O5S
Purity ≥95%
Target DPP-4
Solubility DMSO 11 mg/mL; Water <1 mg/mL; Ethanol <1 mg/mL
Storage 3 years -20C powder
Overview of Clinical Research

<span style=”color:#000000;”><span style=”font-size:12px;”><span style=”font-family:arial,helvetica,sans-serif;”>Glimepiride is a potassium channel agonist.&nbsp;Sanofi completed the phase III RECOMMEND trial in Type-2 diabetes mellitus (combination therapy) in Algeria, Colombia, Egypt, Guatemala, India, Iran, Lebanon, Mexico, Russia, Saudi Arabia, South Africa, Tunisia, Turkey, Ukraine and the United Arab Emirates (NCT01459809) in 2014.</span></span></span>

IUPAC Name 4-ethyl-3-methyl-N-[2-[4-[(4-methylcyclohexyl)carbamoylsulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide
InChI InChI=1S/C24H34N4O5S/c1-4-21-17(3)15-28(22(21)29)24(31)25-14-13-18-7-11-20(12-8-18)34(32,33)27-23(30)26-19-9-5-16(2)6-10-19/h7-8,11-12,16,19H,4-6,9-10,13-15H2,1-3H3,(H,25,31)(H2,26,27,30)
InChIKey WIGIZIANZCJQQY-UHFFFAOYSA-N
SMILES CCC1=C(CN(C1=O)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCC(CC3)C)C
Reference

<br />
1:Pharmacokinetic interactions between glimepiride and rosuvastatin in healthy Korean subjects: does the SLCO1B1 or CYP2C9 genetic polymorphism affect these drug interactions? Observations and introspection of the bioanalysis. Thakkar D, Dash RP.Drug Des Devel Ther. 2017 Apr 20;11:1263-1265. doi: 10.2147/DDDT.S137116. eCollection 2017. No abstract available. PMID: 28461740 Free PMC Article<br />
2:Simultaneous spectrophotometric determination of glimepiride and pioglitazone in binary mixture and combined dosage form using chemometric-assisted techniques. El-Zaher AA, Elkady EF, Elwy HM, Saleh MAEM.Spectrochim Acta A Mol Biomol Spectrosc. 2017 Jul 5;182:175-182. doi: 10.1016/j.saa.2017.03.028. Epub 2017 Mar 14. PMID: 28437738<br />
3:Therapeutic effect of atorvastatin on kidney functions and urinary excretion of Glimepiride in healthy adult human male subjects. Sana T, Aslam B, Aslam N, Ashraf MM, Ashraf A, Malik TA, Niazi SG, Tahir IM, Rehman MR, Ahmed H.Pak J Pharm Sci. 2016 Nov;29(6(Suppl)):2321-2326. PMID: 28375090<br />
4:Enhanced oral bioavailability and sustained delivery of glimepiride via niosomal encapsulation: in-vitro characterization and in-vivo evaluation. Mohsen AM, AbouSamra MM, ElShebiney SA.Drug Dev Ind Pharm. 2017 Apr 6:1-11. doi: 10.1080/03639045.2017.1310224. [Epub ahead of print] PMID: 28330377<br />
5:Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged&thinsp;&ge;&thinsp;60&thinsp;years (START-J trial). Terauchi Y, Yamada Y, Ishida H, Ohsugi M, Kitaoka M, Satoh J, Yabe D, Shihara N, Seino Y.Diabetes Obes Metab. 2017 Mar 9. doi: 10.1111/dom.12933. [Epub ahead of print] PMID: 28294488<br />
6:Formulation and Evaluation of New Glimepiride Sublingual Tablets. Al-Madhagi W, Abdulbari Albarakani A, Khaled Alhag A, Ahmed Saeed Z, Mansour Noman N, Mohamed K.J Pharm (Cairo). 2017;2017:3690473. doi: 10.1155/2017/3690473. Epub 2017 Feb 5. PMID: 28261517 Free PMC Article<br />
7:Pharmacokinetic interactions between glimepiride and rosuvastatin in healthy Korean subjects: does the <i>SLCO1B1</i> or <i>CYP2C9</i> genetic polymorphism affect these drug interactions? Kim CO, Oh ES, Kim H, Park MS.Drug Des Devel Ther. 2017 Feb 23;11:503-512. doi: 10.2147/DDDT.S129586. eCollection 2017. PMID: 28260863 Free PMC Article<br />
8:Therapeutic effect of atorvastatin on kidney functions and urinary excretion of Glimepiride in healthy adult human male subjects. Sana T, Aslam B, Aslam N, Ashraf MM, Ashraf A, Malik TA, Niazi SG, Tahir IM, RiazurRehman M, Ahmed H.Pak J Pharm Sci. 2016 Nov;29(6(Suppl)):2321-2326. PMID: 28167473<br />
9:A validated LC-MS/MS method for the estimation of glimepiride and pitavastatin in rat plasma: Application to drug interaction studies. Surendran S, Paul D, Sushmita R, Krishna L, Tiwari NK, Giri S, Satheeshkumar N.J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Mar 1;1046:218-225. doi: 10.1016/j.jchromb.2017.01.009. Epub 2017 Jan 9. PMID: 28159531<br />
10:Development of Solid-Phase Extraction and HPLC Method for Simultaneous Estimation of Ilaprazole and Glimepiride in Rat Plasma: Application to Pharmacokinetic Studies. Dewani AP, Tripathi AS, Shelke PG, Bakal RL, Mohale DS, Chandewar AV.J Chromatogr Sci. 2017 Mar 1;55(3):327-333. doi: 10.1093/chromsci/bmw189. PMID: 28069690

Request a Quote